EFFICACY AND SAFETY OF ENZYME REPLACEMENT THERAPY IN CHILDREN WITH MUCOPOLYSACCHARIDOSIS TYPE I, II, AND VI: A SINGLE-CENTER COHORT STUDY

Background. There are limited data on the efficacy of long-term enzyme replacement therapy (ERT) in children with mucopolysaccharidosis (MPS).Objective. Our aim was to study the efficacy and safety of long-term ERT in children with MPS type I, II, and VI.Methods. We analyzed the results of ERT with...

Full description

Bibliographic Details
Published in:	Вопросы современной педиатрии
Main Authors:	Liliia A. Osipova, Ludmila M. Kuzenkova, Leyla S. Namazova-Baranova, Anait K. Gevorkyan, Tatiana V. Podkletnova, Nikolay A. Mayanskiy, Grigoriy V. Revunenkov, Nato D. Vashakmadze
Format:	Article
Language:	English
Published:	"Paediatrician" Publishers LLC 2018-04-01
Subjects:	children mucopolysaccharidosis enzyme replacement therapy laronidase idursulfase galsulfase glycosaminoglycans
Online Access:	https://vsp.spr-journal.ru/jour/article/view/1868

Similar Items

Efficacy and safety of a biosimilar laronidase versus the reference laronidase in patients with mucopolysaccharidosis type I
by: Ali Rabbani, et al.
Published: (2025-08-01)

Mucopolysaccharidoses at Bab-el-Oued University Hospital: management, evolution and budgetary impact.
by: Sarah IGUEBLALENE, et al.
Published: (2024-06-01)

Home treatment of type VI mucopolysaccharidosis (Maroteaux‐Lamy syndrome) an alternative at this time of COVID‐19 pandemic: A case in Peru
by: Jenny Lucy Cortez Miranda, et al.
Published: (2020-12-01)

Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II
by: Julia G. Levina, et al.
Published: (2021-12-01)

Mucopolysaccharidosis type II: Enzyme Replacement Therapy Efficiency
by: Nato D. Vashakmadze, et al.
Published: (2020-02-01)

Non-Neuropathic Form of Mucopolysaccharidosis Type II: Clinical Cases
by: Nato D. Vashakmadze, et al.
Published: (2021-03-01)

Idursulfase Beta (Hunterase) Therapeutic Experience in a Patient with Mucopolysaccharidosis Type II
by: Nato D. Vashakmadze, et al.
Published: (2023-08-01)

Clinical Case of Drug Allergy to Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II
by: Julia G. Levina, et al.
Published: (2022-07-01)

Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up
by: Mahoko Furujo, et al.
Published: (2017-12-01)

Results of 14-year-long Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II: Clinical Case
by: Natalia V. Zhurkova, et al.
Published: (2023-01-01)

Enzyme Replacement Therapy with Idursulfase in Patients with Mucopolysaccharidosis Type II: Literature Review
by: Nato D. Vashakmadze, et al.
Published: (2021-12-01)

Case Report: Mucopolysaccharidosis Type I Treatment With α-L-Iduronidase Replacement Therapy
by: Ying Li, et al.
Published: (2022-04-01)

Early Diagnosis and Results of Enzyme Replacement Therapy in the Patient with Mucopolysaccharidosis Type VI: Clinical Case
by: Dmitry V. Ivanov, et al.
Published: (2021-12-01)

Experience of Idursulfase Beta Administration in the Child with Mucopolysaccharidosis Type II: Clinical Case
by: Tatiana K. Kruchina, et al.
Published: (2020-12-01)

Orthopedic Pathology in Children with Mucopolysaccharidosis Type I
by: Nato D. Vashakmadze, et al.
Published: (2016-12-01)

Clinical investigator perspectives on patient outcomes in children with neuronopathic mucopolysaccharidosis II during intrathecal idursulfase-IT treatment
by: Karen S. Yee, et al.
Published: (2024-04-01)

Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II
by: Karen S. Yee, et al.
Published: (2024-03-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Clinical Characteristics of a Patient with Mucopolysaccharidosis Type IVA (Morquio Syndrome)
by: Nato D. Vashakmadze, et al.
Published: (2023-01-01)

The Interplay of Glycosaminoglycans and Cysteine Cathepsins in Mucopolysaccharidosis
by: Alexis David, et al.
Published: (2023-03-01)

Recovery of Vision following Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II, Hunter Syndrome
by: Ryutaro Yamanishi, et al.
Published: (2019-06-01)

CARDIOVASCULAR PATHOLOGY IN CHILDREN WITH TYPE I MUCOPOLYSACCHARIDOSIS
by: N. D. Vashakmadze, et al.
Published: (2014-07-01)

Levels of glycosaminoglycans in the cerebrospinal fluid of healthy young adults, surrogate-normal children, and Hunter syndrome patients with and without cognitive impairment
by: Christian J. Hendriksz, et al.
Published: (2015-12-01)

A Retrospective Study of Mucopolysaccharidosis Type II in Brazil - Data from Brazilian Health System (DATASUS)
by: Fernanda Tenório, et al.
Published: (2023-10-01)

Atypical presentation of mucopolysaccharidosis type IVA
by: Eric T. Rush
Published: (2016-09-01)

Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: A case series
by: Mei-Yan Chan, et al.
Published: (2023-09-01)

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients
by: R. Giugliani, et al.
Published: (2017-09-01)

A post hoc analysis of Projected Retained Ability Scores (PRAS) for the longitudinal assessment of cognitive functioning in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT
by: Karen S. Yee, et al.
Published: (2023-11-01)

A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature
by: Vincenza Gragnaniello, et al.
Published: (2022-06-01)

EFFECTIVENESS OF MODERN METHODS OF TREATING TYPE I MUCOPOLYSACCHARIDOSIS PATIENTS
by: L. S. Namazova-Baranova, et al.
Published: (2014-11-01)

Mucopolysaccharidosis type II (Hunter syndrome) in a boy from the Republic of Serbia: A case report
by: Tubić-Vukajlović Jovana M., et al.
Published: (2023-01-01)

Initiation of fluoxetine in a pediatric patient with Mucopolysaccharidosis IIIA: Early observations
by: Lindsay Torrice, et al.
Published: (2024-09-01)

Neuronopathic Types of Mucopolysaccharidoses: Pathogenesis and Emerging Treatments
by: L. A. Osipova, et al.
Published: (2015-11-01)

Electromyography in diagnostic of median nerve lesion in carpal tunnel syndrome of children with mucopolysaccharidoses
by: A. L. Kurenkov, et al.
Published: (2015-02-01)

The Impact of Enzyme-Replacement Therapy on Upper Airway Obstruction in Children with Mucopolysaccharidoses: Retrospective Cohort Study
by: Liliya A. Osipova, et al.
Published: (2018-05-01)

Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series
by: Hsiang-Yu Lin, et al.
Published: (2016-06-01)

Modern Approaches to the Management of Children with Mucopolysaccharidosis Type I
by: Galina V. Baidakova, et al.
Published: (2022-10-01)

Combination Treatment for Severe Forms of Mucopolysaccharidosis, Type I (Hurler Syndrome): Case Report
by: Nato V. Vashakmadze, et al.
Published: (2023-12-01)

Diagnostic Difficulties of Mucopolysaccharidosis Type I Mild Forms: Clinical Cases
by: Nato D. Vashakmadze, et al.
Published: (2020-06-01)

Surgical treatment of craniovertebral stenosis in patients with mucopolysaccharidosis type I, II, and VI
by: Sergey P. Mironov, et al.
Published: (2018-12-01)